Drug Profile
Research programme: stroke therapeutics - Aida Pharmaceuticals
Alternative Names: SY 02Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aida Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Stroke in China
- 27 Jul 2006 Preclinical trials in Stroke in China (unspecified route)